Role of endothelin in the cardiovascular system

Pharmacological Research

Volumn 63, Issue 6, 2011, Pages 463-472

  Rodríguez Pascual, Fernando ^a,b   Busnadiego, Oscar ^a   Lagares, David ^a   Lamas, Santiago ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Institut Català de Ciències Cardiovasculars   (Spain)

Author keywords

Cardiovascular diseases; Endothelin; Endothelin receptor antagonists; Endothelium

Indexed keywords

AMBRISENTAN; BOSENTAN; DARUSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; MESSENGER RNA; SITAXSENTAN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GATA 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG EFFICACY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; LIVER TOXICITY; NONHUMAN; NUCLEOTIDE BINDING SITE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SMOOTH MUSCLE FIBER; ULCER; UPREGULATION;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 79958055739     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.01.014     Document Type: Review

References (140)

1. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008;86:485-98.
2. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851-76. (Pubitemid 32385909)
3. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-2. (Pubitemid 120015147)
4. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-5. (Pubitemid 120015148)
5. Thorin E, Webb DJ. Endothelium-derived endothelin-1. Pflugers Arch 2010;459:951-8.
6. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999;61:391-415. (Pubitemid 29143176)
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5. (Pubitemid 18090241)
8. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 2000;105:1373-82. (Pubitemid 30322403)
9. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald HR. Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J Exp Med 2007;204:2629-39. (Pubitemid 350044788)
10. Maurer M, Wedemeyer J, Metz M, Piliponsky AM, Weller K, Chatterjea D, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004;432:512-6. (Pubitemid 39576533)
11. Macarthur H, Warner TD, Wood EG, Corder R, Vane JR. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun 1994;200:395-400. (Pubitemid 24183621)
12. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of weibel-palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:1002-7. (Pubitemid 43732104)
13. Goel A, Su B, Flavahan S, Lowenstein CJ, Berkowitz DE, Flavahan NA. Increased endothelial exocytosis and generation of endothelin-1 contributes to constriction of aged arteries. Circ Res 2010;107:242-51.
14. Stow LR, Jacobs ME, Wingo CS, Cain BD. Endothelin-1 gene regulation. FASEB J 2011;25:16-28.
15. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989;264:14954-9. (Pubitemid 19237323)
16. Lee ME, Dhadly MS, Temizer DH, Clifford JA, Yoshizumi M, Quertermous T. Regulation of endothelin-1 gene expression by Fos and Jun. J Biol Chem 1991;266:19034-9. (Pubitemid 21908188)
17. Emori T, Hirata Y, Imai T, Ohta K, Kanno K, Eguchi S, et al. Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. Biochem Pharmacol 1992;44:2409-11. (Pubitemid 23005649)
18. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992;19:753-7.
19. Marsden PA, Dorfman DM, Collins T, Brenner BM, Orkin SH, Ballermann BJ. Regulated expression of endothelin 1 in glomerular capillary endothelial cells. Am J Physiol 1991;261:F117-25.
20. Wilson DB, Dorfman DM, Orkin SH. A nonerythroid GATA-binding protein is required for function of the human preproendothelin-1 promoter in endothelial cells. Mol Cell Biol 1990;10:4854-62.
21. Hieda HS, Gomez-Sanchez CE. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not. Life Sci 1990;47:247-51. (Pubitemid 20243805)
22. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991;88:1054-7.
23. Hu J, Discher DJ, Bishopric NH, Webster KA. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 1998;245:894-9. (Pubitemid 28414014)
24. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, et al. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989;159:1435-40. (Pubitemid 19101142)
25. Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res 2003;92:1288-95. (Pubitemid 36773470)
26. Kawana M, Lee ME, Quertermous EE, Quertermous T. Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol Cell Biol 1995;15:4225-31.
27. Rodriguez-Pascual F, Reimunde FM, Redondo-Horcajo M, Lamas S. Transforming growth factor-beta induces endothelin-1 expression through activation of the Smad signaling pathway. J Cardiovasc Pharmacol 2004;44(Suppl 1):S39-42.
28. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem 2001;276:12645-53.
29. Chao HH, Juan SH, Liu JC, Yang HY, Yang E, Cheng TH, et al. Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. Eur J Pharmacol 2005;515:1-9. (Pubitemid 40779261)
30. Cheng TH, Lin JW, Chao HH, Chen YL, Chen CH, Chan P, et al. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol 2010;139:42-9.
31. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402. (Pubitemid 29409616)
32. Drunat S, Moatti N, Demuth K. Homocysteine decreases endothelin-1 expression by interfering with the AP-1 signaling pathway. Free Radic Biol Med 2002;33:659-68. (Pubitemid 35245838)
33. Wort SJ, Ito M, Chou PC, Mc Master SK, Badiger R, Jazrawi E, et al. Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappa-b binding and histone acetylation at specific kappa-b sites. J Biol Chem 2009;284:24297-305.
34. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, et al. Endothelin 1 transcription is controlled by nuclear factor-kappa-b in age-stimulated cultured endothelial cells. Diabetes 2000;49:1561-70.
35. Strait KA, Stricklett PK, Kohan RM, Kohan DE. Identification of two nuclear factor of activated T-cells (NFAT)-response elements in the 5′-upstream regulatory region of the ET-1 promoter. J Biol Chem 2010;285:28520-8.
36. Harats D, Kurihara H, Belloni P, Oakley H, Ziober A, Ackley D, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest 1995;95:1335-44.
37. Aitsebaomo J, Kingsley-Kallesen ML, Wu Y, Quertermous T, Patterson C. Vezf1/DB1 is an endothelial cell-specific transcription factor that regulates expression of the endothelin-1 promoter. J Biol Chem 2001;276:39197-205.
38. Xiong JW, Leahy A, Lee HH, Stuhlmann H. Vezf1: A Zn finger transcription factor restricted to endothelial cells and their precursors. Dev Biol 1999;206:123-41. (Pubitemid 29100470)
39. Yang Z, Li JC. Stimulation of endothelin-1 gene expression by insulin via phosphoinositide-3 kinase-glycogen synthase kinase-3-beta signaling in endothelial cells. Life Sci 2008;82:512-8.
40. Mawji IA, Robb GB, Tai SC, Marsden PA. Role of the 3′-untranslated region of human endothelin-1 in vascular endothelial cells. Contribution to transcript lability and the cellular heat shock response. J Biol Chem 2004;279:8655-67. (Pubitemid 38295921)
41. Reimunde FM, Castanares C, Redondo-Horcajo M, Lamas S, Rodriguez-Pascual F. Endothelin-1 expression is strongly repressed by AU-rich elements in the 3′-untranslated region of the gene. Biochem J 2005;387:763-72. (Pubitemid 40685711)
42. Rodriguez-Pascual F, Redondo-Horcajo M, Magan-Marchal N, Lagares D, Martinez-Ruiz A, Kleinert H, et al. Glyceraldehyde-3-phosphate dehydrogenase regulates endothelin-1 expression by a novel, redox-sensitive mechanism involving mRNA stability. Mol Cell Biol 2008;28:7139-55.
43. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, et al. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 2010;56:121-8.
44. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-8.
45. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993;68:600-28. (Pubitemid 23202790)
46. Davenport AP. International union of pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 2002;54:219-26.
47. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, et al. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 2006;48:286-93. (Pubitemid 44309825)
48. Kelland NF, Bagnall AJ, Morecroft I, Gulliver-Sloan FH, Dempsie Y, Nilsen M, et al. Endothelial ETB limits vascular remodelling and development of pulmonary hypertension during hypoxia. J Vasc Res 2010;47:16-22.
49. Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, et al. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol 2010;88:644-51.
50. Sauvageau S, Thorin E, Villeneuve L, Dupuis J. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels. Pulm Pharmacol Ther 2009;22:311-7.
51. Avedanian L, Riopel J, Bkaily G, Nader M, D'Orleans-Juste P, Jacques D. ETA receptors are present in human aortic vascular endothelial cells and modulate intracellular calcium. Can J Physiol Pharmacol 2010;88:817-29.
52. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett Jr JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
53. Ferri C, Bellini C, Desideri G, Mazzocchi C, De Siati L, Santucci A. Elevated plasma and urinary endothelin-1 levels inhumansalt-sensitive hypertension. Clin Sci (Lond) 1997;93:35-41. (Pubitemid 27313379)
54. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004;110:2233-40. (Pubitemid 39372507)
55. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 2007;50:621-8. (Pubitemid 350307030)
56. Bohm F, Ahlborg G, Johansson BL, Hansson LO, Pernow J. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:674-9. (Pubitemid 34408752)
57. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-6. (Pubitemid 28135337)
58. Morbidelli L, Orlando C, Maggi CA, Ledda F, Ziche M. Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 1995;269:H686-95.
59. Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. J Biol Chem 1997;272:1747-52. (Pubitemid 27043263)
60. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1703-11.
61. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36. (Pubitemid 29181195)
62. Castanares C, Redondo-Horcajo M, Magan-Marchal N, ten Dijke P, Lamas S, Rodriguez-Pascual F. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J Cell Sci 2007;120:1256-66. (Pubitemid 46711844)
63. Wright CE, Fozard JR. Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats. Eur J Pharmacol 1988;155:201-3.
64. Lipa JE, Neligan PC, Perreault TM, Baribeau J, Levine RH, Knowlton RJ, et al. Vasoconstrictor effect of endothelin-1 in human skin: Role of ETA and ETB receptors. Am J Physiol 1999;276:H359-67.
65. Batra VK, McNeill JR, Xu Y, Wilson TW, Gopalakrishnan V. ETB receptors on aortic smooth muscle cells of spontaneously hypertensive rats. Am J Physiol 1993;264:C479-84.
66. Kassab S, Miller MT, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in dahl salt-sensitive rats. Hypertension 1998;31:397-402.
67. Ikeda T, Ohta H, Okada M, Kawai N, Nakao R, Siegl PK, et al. Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1-receptor antagonist, MK-954. J Cardiovasc Pharmacol 2000;36:S337-41.
68. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001;14:83S-9S.
69. Jasmin JF, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ETA/B and a selective ETA antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 2001;103:314-8. (Pubitemid 32095421)
70. Hill NS, Warburton RR, Pietras L, Klinger JR. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997;83:1209-15. (Pubitemid 27433089)
71. Channick R, Badesch DB, Tapson VF, Simonneau G, Robbins I, Frost A, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001;20:262-3.
72. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
73. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550-4. (Pubitemid 23170459)
74. Matsumoto H, Suzuki N, Onda H, Fujino M. Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem Biophys Res Commun 1989;164:74-80. (Pubitemid 19269697)
75. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35. (Pubitemid 41040298)
76. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8. (Pubitemid 34634407)
77. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP. Expression of endothelin peptides and mRNA in the human heart. Clin Sci (Lond) 1996;90:37-46.
78. Mebazaa A, Mayoux E, Maeda K, Martin LD, Lakatta EG, Robotham JL, et al. Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. Am J Physiol 1993;265:H1841-6.
79. Serneri GG, Cecioni I, Vanni S, Paniccia R, Bandinelli B, Vetere A, et al. Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. Circ Res 2000;86:377-85. (Pubitemid 30141755)
80. Takanashi M, Endoh M. Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol 1991;261:H611-9.
81. Meyer M, Lehnart S, Pieske B, Schlottauer K, Munk S, Holubarsch C, et al. Influence of endothelin 1 on human atrial myocardium-myocardial function and subcellular pathways. Basic Res Cardiol 1996;91:86-93.
82. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther 2000;292:449-59. (Pubitemid 30026405)
83. Pieske B, Beyermann B, Breu V, Loffler BM, Schlotthauer K, Maier LS, et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 1999;99:1802-9. (Pubitemid 29181407)
84. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ETA receptor antagonist. Circulation 2000;101:142-7. (Pubitemid 30044252)
85. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 2003;35:871-86. (Pubitemid 36873806)
86. 2+ signaling in guinea-pig ventricular myocytes: role of protein kinase C. J Mol Cell Cardiol 1999;31:631-43.
87. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990;265:20555-62. (Pubitemid 120014043)
88. Hasegawa K, Fujiwara H, Koshiji M, Inada T, Ohtani S, Doyama K, et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996;27:259-64. (Pubitemid 26045924)
89. Arai M, Yoguchi A, Iso T, Takahashi T, Imai S, Murata K, et al. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 1995;268:H2084-91.
90. Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, et al. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994;89:2198-203.
91. Komati H, Maharsy W, Beauregard J, Hayek S, Nemer M. ZFP260 an inducer of cardiac hypertrophy and a nuclear mediator of endothelin-1 signaling. J Biol Chem 2011;286:1508-16.
92. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3):iii3-7.
93. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibro-proliferative diseases. J Clin Invest 2007;117:524-9. (Pubitemid 46348506)
94. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151:831-41. (Pubitemid 27385615)
95. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15:2707-19. (Pubitemid 38691860)
96. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-25. (Pubitemid 32202907)
97. Xu SW, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004;279:23098-103. (Pubitemid 38685614)
98. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-76. (Pubitemid 24234664)
99. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53:506-10. (Pubitemid 24256979)
100. Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006;26:5518-27. (Pubitemid 44036217)
101. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93. (Pubitemid 39643947)
102. Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011;44:1-10.
103. Leask A. Potential therapeutic targets for cardiac fibrosis: TGF-beta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010;106:1675-80.
104. Swigris JJ, Brown KK. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. BioDrugs 2010;24:49-54.
105. Frech T, Hatton N, Markewitz B, Scholand MB, Cawthon R, Patel A. The vascular microenvironment and systemic sclerosis. Int J Rheumatol 2010, doi:10.1155/2010/362868.
106. Muller-Ladner U, Distler O, Ibba-Manneschi L, Neumann E, Gay S. Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 2009;42:587-95.
107. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3):iii19-24.
108. Sulli A, Soldano S, Pizzorni C, Montagna P, Secchi ME, Villaggio B, et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009;36:1235-9.
109. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, Iwasa N, et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010;121:2407-18.
110. Clozel M, Breu V, Gray GA, Loffler BM. In vivo pharmacology of Ro-46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 1993;22(Suppl 8):S377-9.
111. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-31.
112. Rossi GP, Colonna S, Pavan E, Albertin G, Della Rocca F, Gerosa G, et al. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 1999;99:1147-55. (Pubitemid 29120085)
113. Simeone SM, Li MW, Paradis P, Schiffrin EL. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics 2011;43:148-60.
114. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein-E-deficient mice. Proc Natl Acad Sci USA 1998;95:14367-72.
115. Best PJ, McKenna CJ, Hasdai D, Holmes Jr DR, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 1999;99:1747-52. (Pubitemid 29162489)
116. Brunner F, DuToit EF, Opie LH. Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. J Mol Cell Cardiol 1992;24:1291-305. (Pubitemid 23016052)
117. Hasdai D, Kornowski R, Battler A. Endothelin and myocardial ischemia. Cardiovasc Drugs Ther 1994;8:589-99. (Pubitemid 24336462)
118. Brunner F, Opie LH. Role of endothelin-A receptors in ischemic contracture and reperfusion injury. Circulation 1998;97:391-8. (Pubitemid 28074340)
119. Galiuto L, DeMaria AN, Del Balzo U, May-Newman K, Flaim SF, Wolf PL, et al. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000;102:3111-6.
120. Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 1997;33:518-26. (Pubitemid 27092851)
121. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010;122:958-66.
122. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin-A receptor antagonist trial in heart failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347-54. (Pubitemid 38970011)
123. Lüscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure: the heart failure ETA receptor blockade trial (HEAT). Circulation 2002;106:2666-72.
124. Packer M. Multicentre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results of the REACH-1 trial. Circulation (Suppl) 1998;98:1-3.
125. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990;33:306-10. (Pubitemid 20161886)
126. Ak G, Buyukberber S, Sevinc A, Turk HM, Ates M, Sari R, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2001;15:150-7. (Pubitemid 32453172)
127. Dumont AS, Dumont RJ, McNeill JH, Kassell NF, Sutherland GR, Verma S. Chronic endothelin antagonism restores cerebrovascular function in diabetes. Neurosurgery 2003;52:653-60, discussion 659-660.
128. Wolkart G, Stessel H, Saad Z, Kirchengast M, Brunner F. Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Br J Pharmacol 2006;148:671-81. (Pubitemid 43993057)
129. Settergren M, Pernow J, Brismar K, Jorneskog G, Kalani M. Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy. J Vasc Res 2008;45:295-302. (Pubitemid 351793732)
130. Kalani M, Pernow J, Bragd J, Jorneskog G. Improved peripheral perfusion during endothelin-A receptor blockade in patients with type 2 diabetes and critical limb ischemia. Diabetes Care 2008;31:e56.
131. Ortmann J, Nett PC, Celeiro J, Traupe T, Tornillo L, Hofmann-Lehmann R, et al. Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type 1 diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem Biophys Res Commun 2005;334:689-95. (Pubitemid 40982421)
132. Said SA, Ammar el SM, Suddek GM. Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes. Pharmacol Res 2005;51:107-15.
133. Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481-9.
134. Lattmann T, Hein M, Horber S, Ortmann J, Teixeira MM, Souza DG, et al. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling. Am J Transplant 2005;5:1042-9. (Pubitemid 40571252)
135. Braun C, Conzelmann T, Vetter S, Schaub M, Back WE, Yard B, et al. Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation 1999;68:739-46. (Pubitemid 29468191)
136. Fukunaga K, Takada Y, Taniguchi H, Mei G, Seino KI, Yuzawa K, et al. Endothelin antagonist treatment for successful liver transplantation from non-heartbeating donors. Transplantation 1999;67:328-32. (Pubitemid 29066364)
137. Shennib H, Lee AG, Kuang JQ, Yanagisawa M, Ohlstein EH, Giaid A. Efficacy of administering an endothelin-receptor antagonist (SB209670) in ameliorating ischemia-reperfusion injury in lung allografts. Am J Respir Crit Care Med 1998;157:1975-81.
138. King Jr TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2008;9:1171-9.
139. Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J 2005;272:6297-309. (Pubitemid 41815618)
140. Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza JJ, et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005;97:125-34. (Pubitemid 41033468)